Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON,
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/
New analysis of European CKD non-dialysis patient chart data reveals notable differences in nephrologists’ use of renal therapies, including SGLT2
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be
